ProCE Banner Activity

CE

Navigating the New Advances in CAR T-Cell Therapy: Clinical Applications for Nursing Practice

Video

Watch this on-demand webcast featuring nursing expert insights on best practices for the care of patients receiving CAR T-cells for hematologic malignancies, including identifying eligible patients and managing long-term toxicities.

Nurses: 1.00 Nursing contact hour

Released: March 16, 2023

Expiration: March 15, 2024

No longer available for credit.

Share

Faculty

Kathryn Ciccolini

Kathryn Ciccolini, DNP, AGACNP-BC, OCN

Clinical Program Manager
Nurse Practitioner
Bone Marrow Transplant and Cellular Therapy Service
Mount Sinai Hospital
New York, New York

Linda Ramsdell

Linda Ramsdell, MSN, FNP-BC, OCN

Assistant Program Director 
Immune Effector Cellular Therapy
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Target Audience

This program is intended for hematology/oncology nurses and other healthcare professionals who care for patients with hematologic malignancies who could benefit from CAR T-cell therapies.

Program Learning Goal

The goal of this activity is to improve the knowledge of hematology/oncology nurses, their ability to educate patients, and their competence in caring for patients with hematologic malignancies who have been prescribed CAR T-cell therapy or those who could benefit from CAR T-cell therapies

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the biologic principles underlying CAR T-cell therapy; the structure and function of the CAR; and the similarities and differences between currently available and emerging CAR T-cell therapies

  • Integrate current data, indications, and guideline recommendations on CAR T-cell therapies for patients with leukemia, B-cell lymphomas, myeloma, or CLL/SLL into nursing practice

  • Identify patients who may benefit from treatment or enrollment on a clinical trial investigating CAR T-cell therapy 

  • Manage toxicities associated with CAR T-cell therapy using available guidelines, online clinical resources, and tools

  • Discuss with patients what to expect during CAR T-cell therapy process and the potential related complications following treatment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Kathryn Ciccolini, DNP, AGACNP-BC, OCN: consultant/speaker: Atheneum, Bristol Myers Squibb, Fenix, GLG.

Linda Ramsdell, MSN, FNP-BC, OCN, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 16, 2023, through March 15, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.